30478-91-2 Usage
Uses
Used in Pharmaceutical Industry:
6-MethylnicotinicacidN-oxide is used as a building block for the synthesis of various drugs and compounds, contributing to the development of new pharmaceuticals.
Used in Research and Development:
6-MethylnicotinicacidN-oxide is used as a research compound for studying its potential anti-inflammatory and neuroprotective properties, with the aim of discovering new therapeutic applications.
Used in Drug Development:
6-MethylnicotinicacidN-oxide is used in the development of new drugs, leveraging its unique chemical properties and potential pharmacological effects to create novel medical treatments.
Used in Medical Research:
6-MethylnicotinicacidN-oxide is employed in medical research to explore its biological activities and therapeutic potential, with ongoing studies aiming to uncover its full range of applications in the medical field.
Check Digit Verification of cas no
The CAS Registry Mumber 30478-91-2 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 3,0,4,7 and 8 respectively; the second part has 2 digits, 9 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 30478-91:
(7*3)+(6*0)+(5*4)+(4*7)+(3*8)+(2*9)+(1*1)=112
112 % 10 = 2
So 30478-91-2 is a valid CAS Registry Number.
30478-91-2Relevant academic research and scientific papers
Structure-based design, synthesis, and biological evaluation of imidazo[1,2-b]pyridazine-based p38 MAP kinase inhibitors
Kaieda, Akira,Takahashi, Masashi,Takai, Takafumi,Goto, Masayuki,Miyazaki, Takahiro,Hori, Yuri,Unno, Satoko,Kawamoto, Tomohiro,Tanaka, Toshimasa,Itono, Sachiko,Takagi, Terufumi,Hamada, Teruki,Shirasaki, Mikio,Okada, Kengo,Snell, Gyorgy,Bragstad, Ken,Sang, Bi-Ching,Uchikawa, Osamu,Miwatashi, Seiji
, p. 647 - 660 (2018/01/03)
We identified novel potent inhibitors of p38 MAP kinase using structure-based design strategy. X-ray crystallography showed that when p38 MAP kinase is complexed with TAK-715 (1) in a co-crystal structure, Phe169 adopts two conformations, where one intera
